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Abstract
Background: It has recently become evident that circulating thyroid antibodies are found in
excess among patients suffering from mood disorders. Moreover, a manic episode associated with
Hashimoto's thyroiditis has recently been reported as the first case of bipolar disorder due to
Hashimoto's encephalopathy. We report a case in which Hashimoto's thyroiditis was suspected to
be involved in the deteriorating course of mood disorder and discuss potential pathogenic
mechanisms linking thyroid autoimmunity with psychopathology.
Case presentation: A 43-year-old woman, with a history of recurrent depression since the age
of 31, developed manic, psychotic, and soft neurological symptoms across the last three years in
concomitance with her first diagnosis of Hashimoto's thyroiditis. The patient underwent a
thorough medical and neurological workup. Circulating thyroperoxidase antibodies were highly
elevated but thyroid function was adequately maintained with L-thyroxine substitution. EEG was
normal and no other signs of current CNS inflammation were evidenced. However, brain magnetic
resonance imaging evidenced several non-active lesions in the white matter from both
hemispheres, suggestive of a non-specific past vasculitis. Brain single-photon emission computed
tomography showed cortical perfusion asymmetry particularly between frontal lobes.
Conclusion:  We hypothesize that abnormalities in cortical perfusion might represent a
pathogenic link between thyroid autoimmunity and mood disorders, and that the rare cases of
severe Hashimoto's encephalopathy presenting with mood disorder might be only the tip of an
iceberg.
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Background
A recent twin study has supported the hypothesis that
autoimmune Hashimoto's thyroiditis may be part of the
genetic vulnerability (or an endophenotype) for bipolar
disorder [1]. The twin study was prompted by the previ-
ous report of circulating thyroperoxidase antibodies
(TPO-Abs) in 28% of 226 bipolar outpatients participat-
ing in the Stanley Foundation Bipolar Network in the
United States and the Netherlands compared with 13% of
controls [2].
Here we describe a case of a patient with bipolar psychosis
and Hashimoto's thyroiditis who underwent a thorough
medical and neurological workup. We found abnormali-
ties in cortical perfusion that we hypothesize might repre-
sent a pathogenic link between thyroid autoimmunity
and mood disorders.
Case presentation
The patient, a 43-year-old housewife, first came to the out-
patient unit of the department of neurosciences in 2005.
She had suffered from mood disorder since the age of 31
and had been treated repeatedly with antidepressants
across the following 9 years. Her level of functioning prior
to illness had been adequate, subsequently returning to a
similar level after recovery from episodes. During a hospi-
talization at a dermatology unit at age 37 for urticaria vas-
culitis, an endocrinological consult led to the first
diagnosis of Hashimoto's thyroiditis. On palpation, thy-
roid had been found increased in volume and hard-elastic
in consistency. Ultrasound had revealed increased volume
of the gland and a diffuse non-homogeneous echopattern.
TPO-abs were abnormally elevated, while thyroglobuline
antibodies (TG-Abs) were normal. Thyroid function tests
had evidenced subclinical hypothyroidism (TSH = 3.68
IU/ml; normal FT3, and low FT4 = 0.74 ng/dl, with nor-
mal range 1.0–1.8 ng/dl). Then, substitution therapy with
L-thyroxine was started for subclinical hypothyroidism.
The course of mood disorder, after the first 9 years of
recurrent episodes of major depression, had worsened
over the last 3 years, when manic and psychotic symptoms
became manifest, even in the absence of ongoing antide-
pressant treatment. In particular, 4 hospitalizations had
been necessary due to severe episodes of both polarities.
According to the hospital records provided, the latter epi-
sodes were characterized, among other symptoms, by
marked anxiety, agitation, somatic complaints, transient
persecutory delusions, and suicidal thoughts. Hospital
diagnoses varied from bipolar disorder I, mixed to bipolar
disorder I, depressive, to affective psychosis, and, last, to
schizoaffective disorder. Since her first diagnosis of bipo-
lar disorder at age 41, Ms. A had been treated with various
regimens including valproate, benzodiazepines, typical
(haloperidol) and atypical (quetiapine, risperidone, ami-
sulpiride) antipsychotics. Carbamazepine had been
stopped after a brief trial because of side effects (nausea
and vomiting), whereas lithium had been until then con-
sidered contraindicated by hypothyroidism.
When first seen at the department of neurosciences, the
patient's symptoms included depressed mood, psycho-
motor retardation, suicidal thoughts, and persecutory
ideas. Moreover, she manifested somnolence, fatigue,
nausea, and ataxia, attributable in part to side effects from
her current mood-stabilizing treatment (sodium val-
proate, 900 mg daily). The patient was also taking daily
chlordemethyldiazepam (3 mg), L-thyroxine (0.075 mg),
whereas risperidone, prescribed during last hospitaliza-
tion, had been stopped 4 weeks earlier. Serum valproate
concentration was found within the therapeutic range
(50.4 μg/ml). Thyroid hormone replacement with L-thy-
roxine was adequate, as serum concentrations of free trii-
odothyronine and thyroxine were normal, as was thyroid
stimulating hormone (TSH) (1.24 IU/ml). TPO-Abs were
highly elevated (>1000 mU/ml; normal range < 35 mU/
ml), while TG-Abs were normal.
Mood-stabilizing medication was changed. Lithium car-
bonate was added and increased gradually, while sodium
valproate was tapered and stopped over a few weeks.
Ataxia, somnolence, nausea, and psychomotor retarda-
tion ameliorated, but the patient manifested anxiety and
agitation in addition to the pre-existing depressed mood
and persecutory ideas. Chlordemethyldiazepam was sub-
stituted with lorazepam and low-dose haloperidol was
prescribed.
During a subsequent visit at the department for measure-
ment of lithium serum concentration, the patient, seem-
ingly only slightly tense at entry, suddenly started to laugh
inappropriately and to cry, maintaining that someone was
coming to kill her. Haloperidol was administered (1 mg
orally) and symptoms promptly resolved. She admitted
that her behavior had been prompted by visual hallucina-
tions ("I have seen dark strangers at the door coming to
take me away"). Similar crises occurred at home over the
following weeks and were treated with low doses of pro-
mazine.
A few weeks later, the patient manifested an episode of
fainting, accompanied with involuntary limb movements.
She was taken to an emergency room where neurological
assessment including EEG ruled out epileptic seizures and
other prominent diseases. Subsequently, the patient
reported weakness, gait problems, and transient involun-
tary movements of the hands (described as myoclonus). A
neurological examination evidenced only moderate
reduction of synkinetic movements of the arms during
walking and mild hypermetry of the finger-nose test on
the right side, interpreted by the neurology consultant asClinical Practice and Epidemiology in Mental Health 2007, 3:31 http://www.cpementalhealth.com/content/3/1/31
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drug-related side-effects. Current psychotropic daily treat-
ment was lithium carbonate 900 mg, lorazepam 7.5 mg,
promazine (72 mg). Lithium serum concentration (12
hours after last administration) was 0.57 mmol/L.
Lithium treatment was maintained, also given high sui-
cide risk, both personal (recurrent suicidal thoughts) and
familial (two first-degree relatives had committed
suicide).
The nature of neurological symptoms, prominent despite
relatively low doses of medication, remained to be clari-
fied. Fainting, gait problems, and myoclonus might have
been "functional" in nature, as those seen in conversion
or somatization disorder; nevertheless, diagnostic proce-
dures aiming at ruling out organic causes were in order. In
particular, as Hashimoto's thyroiditis is often associated
with other autoimmune disorders, a comprehensive med-
ical workup was initiated. Thyroid echographic scan evi-
denced reduced thyroid size (estimated total volume of
5.1 cubic centimeters), with a diffusely non-homogene-
ous echo-pattern, consistent with previous diagnosis of
Hashimoto's thyroiditis. No abnormalities were found in
markers of current inflammation and vasculitis, and in the
following antibodies: anti-nuclear, anti-extractable
nuclear antigens (anti-ribonucleic protein, anti-Smith,
anti-SSA, anti SSB, anti Jo1, anti-Scl-70), anti-DNA, anti-
neutrophil cytoplasmic (c-ANCA and p-ANCA), anti-car-
diolipin, and anti-glutamic acid decarboxylase A. Nailfold
capillaroscopy evidenced a reduced number of capillaries
and an irregularity in pattern, consistent with past
vasculitis.
From a neurological point of view, multiple sclerosis was
the first organic cause to be investigated, being highly
prevalent in Sardinia and often associated with other
autoimmune disorders, including Hashimoto's thyroidi-
tis. Visual, acoustic, and somato-sensorial evoked poten-
tials were found normal.
Brain magnetic resonance imaging (MRI) evidenced sev-
eral small areas of high signal intensity in the white matter
from both hemispheres, in particular in sub-cortical fron-
tal sites. Such areas were not enhanced with paramagnetic
contrast; i.e. were unlikely to be active lesions. They were
suggestive of a non-specific past vasculitis.
The neurology consultant, given the evoked potentials
and MRI findings, did not recommend further diagnostic
procedures for multiple sclerosis, such as a lumbar punc-
ture in the search of immunoglobulin oligoclonal bands.
Brain single-photon emission computed tomography
(SPECT) was requested to better explore cortical perfusion
and function. Thirty minutes after intravenous injection
of the radiopharmaceutical (99 mTc-ethyl cysteinate
dimer – ECD) the patient underwent brain SPECT. The
imaging analysis showed relevant irregularity in cortical
distribution of the tracer regarding both hemispheres
(Figure 1). Cortical perfusion asymmetry was particularly
evidenced between frontal lobes (reduced uptake by the
left side). Areas of reduced cortical uptake were also evi-
denced in both superior gyri of temporal lobes. ECD dis-
tribution was also irregular in basal ganglia while resulted
normal in both cerebellar hemispheres.
The conclusion from overall medical workup was that the
patient might have suffered from vasculitis, with traces left
in periphery (as seen by capillaroscopy) and in cerebral
areas (as seen by MRI). Moreover, she was currently expe-
riencing abnormalities in cortical function, particularly in
frontal lobes, as evidenced by SPECT imaging.
Over the 12 months following the first visit at the depart-
ment, the patient gradually stabilized with maintenance
with lithium, olanzapine, and benzodiazepines. Func-
tioning improved although not returning to pre-morbid
levels. Neuropsychological testing (WAIS-R) placed the
patient in the borderline range of intellectual functioning,
mostly due to impairment in memory retrieval.
Discussion
Abnormalities in thyroid function have been long associ-
ated with psychiatric symptoms, but it has recently
become evident that circulating thyroid antibodies, even
in the absence of hormone abnormalities, are found in
excess among patients suffering from mood and anxiety
disorders [2,3]. A manic episode associated with Hashim-
oto's thyroiditis, pathological EEG and response to short-
term treatment with high doses of prednisolone, has
recently been reported as the first case of bipolar disorder
due to Hashimoto's encephalopathy [4]. The latter is a
rare severe syndrome with different clinical presentations
and course (for review see [5]). Onset may be acute or sub-
acute. Presentation may include alteration of conscious
level, seizures, tremor, myoclonus, ataxia, or multiple
stroke-like episodes. Psychiatric symptoms, including
depression and psychosis, have also been reported [6,7].
Course of Hashimoto's encephalopathy may be relapsing/
remitting or progressive, even evolving into dementia.
Nonspecific imaging abnormalities may be present. Brain
MRI findings may change abruptly and drastically. For
example, reversible MRI lesions in the cerebral white mat-
ter, supposedly reflecting brain edema, have been
reported in one case where antithyroid antibodies were
detected in the cerebrospinal fluid [8]. Even if the patho-
physiology is unknown, the focal and global cerebral
involvement have been attributed to autoimmune-medi-
ated cerebral vasculitis, with or without immune complexClinical Practice and Epidemiology in Mental Health 2007, 3:31 http://www.cpementalhealth.com/content/3/1/31
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deposition [9,10], and an anti-neuronal antibody-medi-
ated mechanism [11].
With regard to brain SPECT imaging, either diffuse hypop-
erfusion not related to specific region [12,13] or focal
hypoperfusion [14] have been described in Hashimoto's
encephalopathy. Similar brain SPECT patterns have been
found in other immunomediated diseases presenting
with neurological and psychiatric symptoms, such as sys-
temic lupus erythematosus, as the probable expression of
autoimmune involvement of brain due to vasculitis and/
or anti-neuron autoantibodies [15].
A limitation of this case report is that we cannot prove
causality between Hashimoto's thyroiditis and abnormal-
ities in cortical perfusion and cannot rule out that the
described association was only by chance, considering the
high prevalence of Hashimoto's thyroiditis. However, it is
noteworthy that cortical hypoperfusion was also found in
brain SPECT imaging from series of patients with euthy-
roid autoimmune thyroiditis, even in the absence of any
treatment or clinical evidence of CNS involvement
[16,17]. Abnormalities were reported either with no top-
ographic pattern [16] or with preferential localization in
the frontal lobes [17]. In their series of patients with
euthyroid thyroiditis, Zettinig and coworkers [16] found
no association with depression and concluded that the
presence of cerebral vasculitis was the most likely patho-
genic model explaining cerebral hypoperfusion, as
already found in cases of Hashimoto's encephalopathy.
Conclusion
We hypothesize that abnormalities in cortical perfusion
might represent a pathogenic link between Hashimoto's
Brain SPECT transaxial images showing diffuse patchy cortical distribution of 99 mTc-ECD, in particular significant cortical  hypoperfusion in the left frontal lobe and in both temporal lobes (arrows) Figure 1
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thyroiditis and mood disorders, even in the absence of
other prominent symptoms of current CNS inflammation
or EEG abnormalities, as in the described case. Accord-
ingly, the rare severe cases of Hashimoto's encephalopa-
thy presenting with mood disorder [4,6,7] may represent
only the tip of an iceberg.
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